Rahway-based pharma giant Merck plans to spend $6.7 billion to purchase Terns Pharmaceuticals in an effort to boost its hematology pipeline. As part of the deal, Merck gains access to an experimental ...

Merck has built a bullish view on sacituzumab tirumotecan across multiple cancer types based on promising data from other TROP2 antibody-drug conjugates and from its partner Kelun-Biotech in China.

March 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday it would buy biotech firm Terns Pharma (TERN.O), opens new tab for $6.7 billion, as the drugmaker races to bolster its cancer ...

Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion. This is the third multibillion-dollar acquisition for Merck over the past year as it looks to ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Merck said Friday it would buy ...

Merck & Co. Inc. MRK is nearing an all-cash deal to acquire Terns Pharmaceuticals, Inc. TERN for roughly $6 billion, aiming to strengthen its oncology pipeline ahead of Keytruda losing U.S. patent ...